pharma · Carcinoma, Renal Cell · Human Immunodeficiency Virus (HIV) Infection
Merck KGaA, Darmstadt
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt clinical programs — 23 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Frankfurter Str. 250, Darmstadt, 64293, DE
- Employees
- 7,364
- Programs
- 63
- Drugs
- 50
- Patents
- 0
Merck KGaA, Darmstadt projects
23 ClinicalTrials.gov programs sponsored by Merck KGaA, Darmstadt.
Merck KGaA, Darmstadt has 23 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Belzutifan
Merck KGaA, Darmstadt, Germany
Carcinoma, Renal Cell
1 trial -
Cetuximab
Merck KGaA, Darmstadt, Germany
Metastatic Colorectal Cancer
1 trial -
DOR/ISL
Merck KGaA, Darmstadt, Germany
HIV-1 Infection
1 trial -
Daptomycin for Injection
Merck KGaA, Darmstadt, Germany
Bacteremia
1 trial -
Docetaxel
Merck KGaA, Darmstadt, Germany
Castration-Resistant Prostatic Cancer
1 trial -
Doravirine
Merck KGaA, Darmstadt, Germany
Human Immunodeficiency Virus (HIV) Infection
1 trial -
Efinopegdutide
Merck KGaA, Darmstadt, Germany
Non-alcoholic Fatty Liver Disease
1 trial -
Efinopegdutide 20 mg/mL
Merck KGaA, Darmstadt, Germany
Nonalcoholic Fatty Liver Disease
1 trial -
Intismeran autogene
Merck KGaA, Darmstadt, Germany
Malignant Melanoma
1 trial -
M5049 low dose
Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
1 trial -
MK-1167
Merck KGaA, Darmstadt, Germany
Alzheimer Disease
1 trial -
MK-2214
Merck KGaA, Darmstadt, Germany
Early Alzheimer's Disease
1 trial -
MK-6194
Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
1 trial -
Miransertib
Merck KGaA, Darmstadt, Germany
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
1 trial -
Paclitaxel
Merck KGaA, Darmstadt, Germany
Esophageal Squamous Cell Carcinoma
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Melanoma
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Advanced Non-Small Cell Lung Cancer
1 trial -
Pembrolizumab (+) Berahyaluronidase alfa
Merck KGaA, Darmstadt, Germany
Squamous Cell Carcinoma
1 trial -
Pembrolizumab 200 mg
Merck KGaA, Darmstadt, Germany
Non-small Cell Lung Cancer
1 trial -
Pembrolizumab 200 mg
Merck KGaA, Darmstadt, Germany
Metastatic Castration-Resistant Prostate Cancer
1 trial -
Pembrolizumab/Vibostolimab coformulation
Merck KGaA, Darmstadt, Germany
Metastatic Non Small Cell Lung Cancer
1 trial -
Raludotatug Deruxtecan (R-DXd)
Merck KGaA, Darmstadt, Germany
Gastrointestinal Cancer
1 trial -
alvimopan
Merck KGaA, Darmstadt, Germany
Constipation
1 trial
Frequently asked questions
How many clinical projects does Merck KGaA, Darmstadt have?
23 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.